MedC Biopharma Corporation is rated 3 out of 5 in the category innovation in skin oncology medication. Read and write reviews about MedC Biopharma Corporation. A clinical stage company developing a novel treatment for CTCL, a type of skin cancer which afflicts 100,000 new patients annually. Our R&D is based on a combined effort of Professor Hinanit Koltai, head of medical cannabis research at the national lab in ARO, Israel together with Professor Emmilia Hodek, director of Dermatology, Rabin Medical Center, Israel. Our R&D pipeline includes 2 additional skin oncology indications and anxiety related indications. Head Office in Toronto, Canada R&D in Israel
Address
229 Yonge Street #400 400
Company size
11-50 employees